AU Patent

AU2024236119A1 — Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer

Assigned to Bayer Consumer Care AG · Expires 2025-09-25 · 1y expired

What this patent protects

Described herein are methods of treating patients with biochemical recurrence of hormone-sensitive prostate cancer using a drug product comprising an androgen receptor inhibitor, such as darolutamide.

USPTO Abstract

Described herein are methods of treating patients with biochemical recurrence of hormone-sensitive prostate cancer using a drug product comprising an androgen receptor inhibitor, such as darolutamide.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024236119A1
Jurisdiction
AU
Classification
—
Expires
2025-09-25
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Consumer Care AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.